MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

There are many possible causes for coughing up blood, including acute infections like bronchitis, chronic conditions like cystic fibrosis, a chest or lung injury, pulmonary embolism (blood clot in the ...

United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

We are thrilled to welcome Heather to the Avalyn team and to her new role as Board Chair,” said Lyn Baranowski, chief executive officer of Avalyn. “As we look ahead, we are excited to tap into Heather ...

Financially, Gyre had cash and cash equivalents totaling $15.9 million as of September 30, 2024. For the third quarter of ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).